Emmanuel Patin

11PUBLICATIONS
50CO-AUTHORS
Molecular targetsChemotherapyCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (11)

|Mar 03, 2026
Effects of oncolytic immunotherapy with RP1 (vusolimogene oderparepvec) on immune cells mediate responsiveness to anti-PD-1 via STING-mediated interferon signaling.

Victoria Roulstone, Joan Kyula, Elizabeth Appleton

|Oct 22, 2025
Xevinapant plus Chemoradiotherapy Negatively Sculpts the Tumor-Immune Microenvironment in Head and Neck Cancer.

Charleen Chan Wah Hak, Emmanuel C Patin, Anton Patrikeev

|Sep 26, 2025
Addition of oncolytic virotherapy to clinical isolated limb perfusion for melanoma and sarcoma activates antitumor immunity.

Andrew J Hayes, Emma J Davies, Michelle Wilkinson

|Aug 01, 2025
Tumor control and immune activation through palliative irradiation and ATR inhibition, PATRIOT Part C: a phase Ib trial.

Magnus T Dillon, Emmanuel C Patin, Kabir Mohammed

|Jul 15, 2025
Author Correction: Palbociclib and dsRNA sensor co-operate to enhance anti-cancer effects through ER stress and modulation of immune evasion.

Victoria Roulstone, Joan Kyula-Currie, James Wright

|Jul 08, 2025
The PARP inhibitor talazoparib synergizes with reovirus to induce cancer killing and tumour control in vivo in mouse models.

Joan Kyula-Currie, Victoria Roulstone, James Wright

Pageof 2

Frequent Collaborators

11 joint publications

Kevin J Harrington

10 joint publications

Alan Melcher

6 joint publications

Pablo Nenclares

6 joint publications

Malin Pedersen